Trials / Recruiting
RecruitingNCT05763511
Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 300 (estimated)
- Sponsor
- University of Aarhus · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This project investigates circulating tumor DNA (ctDNA) in patients with suspected ovarian malignancy. We hypothesize that measurement of ctDNA in women with suspected ovarian cancer can improve the diagnostic efficiency for preoperative differentiation between benign and malignant masses. Specifically, we hope to determine the diagnostic efficiency of ctDNA alone and ctDNA in combination with imaging modalities (ultrasonography, MRI, PET-CT) and CA 125 for preoperative differentiation between benign and malignant adnexal masses. Based on this, we hope to develop an improved diagnostic algorithm. The mutational profile and relation to tumour type, stage, treatment response and prognosis will be explored. Analyses of blood and tissue samples will be used to examine the disease development and biology. Blood samples, tumour tissue and data on imaging modalities as well as CA 125 will be collected prospectively in consecutive women referred to Aarhus University Hospital.
Conditions
Timeline
- Start date
- 2022-07-01
- Primary completion
- 2024-12-04
- Completion
- 2029-05-04
- First posted
- 2023-03-10
- Last updated
- 2024-05-09
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT05763511. Inclusion in this directory is not an endorsement.